Shenzhen Changhong Technology Co., Ltd. engages in the design, manufacture, and sale of precision molds and high-precision injection molded plastic parts. Its core products include medical devices and polymer plastic consumables, intelligent manufacturing products, semiconductor consumables, and mold products. The company provides integrated solutions for precision molds and automated production in the medical device, polymer plastics, intelligent manufacturing, and semiconductor sectors. It is recognized for its high-grade medical consumables and has received awards such as the National “Precision Mold Award.” The company primarily serves clients in China, with additional markets including Europe, Vietnam, and the Philippines. Founded in 2004 and headquartered in Shenzhen, Guangdong Province, China, it also maintains strategic relationships with leading domestic wafer factories and semiconductor manufacturers.
Recent developments include Shenzhen Changhong Technology securing certification and ongoing delivery of semiconductor consumable products to major domestic wafer factories, with seven wafer carrier products under research and entering validation stages. The company is preparing for large-scale production in this segment. Its medical consumables sector maintains stable orders supported by long-term client relationships, with steady expansion of new clients and projects. Additionally, Shenzhen Changhong Technology formed a strategic alliance with Sinopec in 2024, marking a key partnership to explore technological innovation and industrial integration. The company reports ongoing efforts to enhance personnel training, ramp up production capacity, and focus on the precision plastic products market due to its larger capacity and growth potential. It mainly serves local markets in China, Vietnam, and the Philippines, with semiconductor business focused exclusively on domestic clients. In its latest quarterly results, the company reported revenue growth with some pressure on net income, reflecting its strategic investments in new product validations and market expansions.